Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Coronaviridae Infections Pipeline Review, H2 2016 - 16 Companies & 31 Molecules - Research and Markets

Research and Markets
Posted on: 28 Sep 16

Research and Markets has announced the addition of the "Coronaviridae Infections - Pipeline Review, H2 2016" report to their offering.

Coronaviridae Infections pipeline therapeutics constitutes close to 31 molecules. Out of which approximately 24 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 13, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Coronaviridae Infections - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Coronaviridae Infections Overview
  3. Therapeutics Development
  4. Pipeline Products for Coronaviridae Infections - Overview
  5. Pipeline Products for Coronaviridae Infections - Comparative Analysis
  6. Coronaviridae Infections - Therapeutics under Development by Companies
  7. Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes
  8. Coronaviridae Infections Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Coronaviridae Infections - Products under Development by Companies
  13. Coronaviridae Infections - Products under Investigation by Universities/Institutes
  14. Coronaviridae Infections - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • CEL-SCI Corporation
  • GeneCure LLC
  • Gilead Sciences, Inc.
  • Hemispherx Biopharma, Inc.
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Nanotherapeutics, Inc.
  • NanoViricides, Inc.
  • Novavax, Inc.
  • Organic Vaccines
  • Phelix Therapeutics, LLC
  • Planet Biotechnology Inc.
  • Protein Sciences Corporation
  • Regeneron Pharmaceuticals Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.